UNSPSC 51122401: Hydroxyzine/pentaerythritol tetranitrate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV250. This VA Drug Class (CV250) classifies this compound as belonging to the group ANTIANGINALS.

UNSPSC 51122401 Hydroxyzine/pentaerythritol tetranitrate is a Commodity code that encompasses pharmaceutical procurement for emergency medical services, state health agencies, and cooperative purchasing alliances. State and local governments buy specific emergency medications and pharmaceutical products under this code through sealed-bid procurements and cooperative purchasing agreements. The work includes supplying branded and generic pharmaceuticals, over-the-counter products, and emergency life-support medications to fire rescue departments, health benefit programs, and multi-jurisdictional state agencies. Issuing bodies range from municipal purchasing departments to state health commissions and multistate cooperative purchasing alliances; the City of Tampa's Fire Rescue, Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear as recent active buyers.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) due April 8, 2026, for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem vials with a one-year contract term and estimated value of $40,000, featuring a 5 percent Small Local Business Enterprise sheltered-market bid discount. The Texas HHS Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting models outside traditional PBM and wholesaler channels. MMCAP issued an RFP (S1070000015802) due March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with effective contract dates of July 1, 2026, and performance-penalty structures of $200 to $1,500 per violation.